# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-25-119251
**Filing Date:** 2025-12
**Character Count:** 7223
**Document Hash:** 36285d0a7e0a63aab196f0d881d13b7e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-119251.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001213900-25-119251

**CONFORMED SUBMISSION TYPE**: 8-A12B/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38793
- **FILM NUMBER:** 251556442

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-A/A**

(Amendment No. 5)

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES<br> PURSUANT TO SECTION 12(b) OR (g) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

**INMUNE BIO INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **47-5205835** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **225 NE Mizner Blvd., Suite 640**<br> **Boca Raton, Florida**  | **33432** |
| (Address of principal executive offices) | (Zip Code) |

---

Securities to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class to be so registered** | **Name of each exchange on which each class is to be registered** |
| **Preferred Stock Purchase Rights** | **The Nasdaq Capital Market** |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates: Not Applicable

Securities registered pursuant to Section 12(g) of the Act: None.

**Explanatory Note**

This Amendment No. 5 to Form 8-A is being filed by the registrant for the purpose of amending and supplementing the description of the registrant's securities contained in the [Form 8-A](http://www.sec.gov/Archives/edgar/data/1711754/000121390020045474/ea132342-8a12b_inmune.htm) filed by the registrant with the U.S. Securities and Exchange Commission (the "SEC") on December 30, 2020, as amended by Forms 8-A/A filed by the registrant with the SEC on [December 21, 2021](http://www.sec.gov/Archives/edgar/data/1711754/000121390021066691/ea152577-8a12ba1_inmune.htm), [December 12, 2022](http://www.sec.gov/Archives/edgar/data/1711754/000121390022079144/ea169922-8a12ba2_inmunebio.htm), [December 18, 2023](http://www.sec.gov/Archives/edgar/data/1711754/000121390023096482/ea189977-8a12ba3_inmunebio.htm) and [December 9, 2024](http://www.sec.gov/Archives/edgar/data/1711754/000121390024106924/ea0223772-8a12ba4_inmune.htm), respectively.

**Item 1. Description of Registrant's Securities to be Registered.**

On December 5, 2025, INmune Bio Inc. (the "Company") entered into Amendment No. 5 (the "Amendment") to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended (the "Rights Agreement"). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Rights Agreement.

The Amendment extended the expiration of the Rights Agreement to December 31, 2026 and provides that such expiration date will automatically extend for successive one-year terms unless the Company's Board of Directors determines not to extend the Rights Agreement.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Rights Agreement and the Amendment, each of which is attached hereto as an exhibit and is incorporated herein by reference.

**Item 2. Exhibits.**

See the Exhibit Index below, which is incorporated by reference herein.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [Rights Agreement, dated as of December 30, 2020 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on December 30, 2020).](http://www.sec.gov/Archives/edgar/data/1711754/000121390020045464/ea132345ex4-1_inmune.htm) |
| 4.2 | [Amendment No. 1 to Rights Agreement, dated as of December 20, 2021, between INmune Bio Inc. and Vstock Transfer LLC (incorporated by reference to the Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 21, 2021).](http://www.sec.gov/Archives/edgar/data/1711754/000121390021066684/ea152576ex4-1_inmunebio.htm) |
| 4.3 | [Amendment No. 2 to Rights Agreement, dated as of December 9, 2022, between INmune Bio Inc. and Vstock Transfer LLC (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 12, 2022)](http://www.sec.gov/Archives/edgar/data/1711754/000121390022079142/ea169921ex4-1_inmunebio.htm) |
| 4.4 | [Amendment No. 3 to Rights Agreement, dated as of December 14, 2023, between INmune Bio Inc. and Vstock Transfer LLC (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 18, 2023)](http://www.sec.gov/Archives/edgar/data/1711754/000121390023096477/ea189976ex4-1_inmunebio.htm) |
| 4.5 | [Amendment No. 4 to Rights Agreement, dated as of December 5, 2025, between INmune Bio Inc. and Vstock Transfer LLC (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 9, 2024)](http://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/ea022377601ex4-1_inmune.htm) |
| 4.6 | <u>[Amendment No. 5 to Rights Agreement, dated as of December 5, 2025, between INmune Bio Inc. and Vstock Transfer LLC (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 8, 2025)](https://www.sec.gov/Archives/edgar/data/1711754/000121390025119217/ea026866701ex4-1_inmune.htm)</u> |

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INMUNE BIO INC.** | **INMUNE BIO INC.** |
| Date: December 8, 2025 |  |  |
|  | By: | /s/ David Moss |
|  | Name: | David Moss |
|  | Title: | Chief Executive Officer |

---